Pulse Biosciences Inc (PLSE)

Form 8-K - Current report

Form 8-K - Current report

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™...

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today...

Form DEF 14A - Other definitive proxy statements

Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today...

Form 8-K - Current report

Form 8-K - Current report

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Accelerates Enrollment Timeline for the Cardiac Catheter IDE Conference Call to Be Held Thursday, May 7th to Discuss Business Updates and...

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Form 8-K - Current report

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

Multicenter results show sustained high durability and procedural efficiency, redefining positive expectations for catheter ablation in patients...